Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 99 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood draw at six months Clear all
Completed No phase listed Observational

Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer

NCT00422500
View directory record Official record
Conditions
Lung Cancer
Interventions
Questionnaire, Telephone Interactive System, Blood Samples
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
4
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Reducing Cardiovascular Disease Risk Factors in Rural Communities in North Carolina

NCT02707432
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Heart Matters
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

NCT06843447
View directory record Official record
Conditions
Ovarian Cancer Recurrent
Interventions
Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication, Pembrolizumab, Gemcitabine, Pegylated liposomal doxorubicin, MK-2010
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Active, not recruiting No phase listed Observational

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

NCT05639556
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BMI and lean mass index from DXA, Anthropometric Measurements, Hand-grip strength, Six-minute walk Test, Sit-to-Stand Test, Short physical performance battery (SPPB), BIA Sub-study, Accelerometry to assess physical activity, Gastrointestinal (GI) and nutrition questionnaires:, Psychosocial questionnaire: PHQ-8, Psychosocial questionnaire: GAD-7, Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ), Psychosocial questionnaire: CF Fatalism Scale, Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA), 12-month Questionnaire, Oral glucose tolerance testing (OGTT), Continuous glucose monitoring (CGM), Chest CT scans (When available within the past 6 months in medical records), Hologic Dual X-Ray Absorptiometry (DXA), Ultrasound Sub-study of assessment of appendage muscles using ultrasound, Psychosocial questionnaire: Hunger Vital Sign questionnaire, Respiratory symptom questionnaire: CRISS, Spirometry, Psychosocial questionnaire: Additional Health Questionnaire, CF Management Questionnaire, Food Frequency Questionnaire
Diagnostic Test · Other · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting No phase listed Observational

COVID-19 Transmission and Morbidity in Malawi

NCT05973084
View directory record Official record
Conditions
SARS CoV 2 Infection, SARS CoV 2 Vaccination
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
5 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Switching From Rituximab to Ocrelizumab in MS Patients

NCT02980042
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Rituximab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics

NCT04226131
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Controls
Interventions
Blood Draw, Disease Activity (DAS-28) Assessment, Skeletal Muscle Mitochondrial Respiratory Capacity, Muscle Biopsy, Body Composition, Cardiopulmonary Exercise Test (CPET), Strength Testing, Questionnaires, Skeletal Muscle Biomechanical Property Assessment
Other
Lead sponsor
Duke University
Other
Eligibility
25 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Phase 2 Interventional

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
Diagnostic Test · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 2 Interventional Results available

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment With Namenda in Women at Risk for Cognitive Decline

NCT00242632
View directory record Official record
Conditions
Dementia
Interventions
Namenda
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

Early Life Exposures Among Children With Sickle Cell Disease

NCT05377372
View directory record Official record
Conditions
Sickle Cell Disease, Adverse Childhood Experiences, Breastfeeding
Interventions
Breastfeeding support group, Observation
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

NCT03655444
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30
Drug · Procedure · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

Abatacept in Juvenile Dermatomyositis

NCT02594735
View directory record Official record
Conditions
Dermatomyositis
Interventions
Abatacept
Drug
Lead sponsor
George Washington University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Phase 3 Interventional

Improving Mobility After Revascularization in Peripheral Artery Disease

NCT06686121
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication, Peripheral Vascular Disease, Mobility Limitation, Revascularization
Interventions
Home Based Exercise, Nitrate Rich Beetroot Juice, Attention Control, Placebo Beetroot Juice Without Nitrate
Behavioral · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
Tucson, Arizona • Downey, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Results available

Metabolic Mapping and Cardiac Resynchronization

NCT03420833
View directory record Official record
Conditions
Heart Failure
Interventions
Cardiac resynchronization therapy pacemaker (CRT-P)
Device
Lead sponsor
Yong-Mei Cha
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00175877
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure

NCT03875768
View directory record Official record
Conditions
Hypertension, Health Behavior
Interventions
Tracking plus coaching
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

Family-Based Weight Wellness Treatment Through Food is Medicine and Group Medical Visits in Pediatric and Adult Primary Care

NCT07717658
View directory record Official record
Conditions
Obesity & Overweight, Weight Management
Interventions
Culinary medicine classes, Medically Tailored Groceries, Shared Medical Appointments
Behavioral
Lead sponsor
Tufts University
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Not applicable Interventional

A Pilot Stress Management Intervention Study for High Risk Children With Asthma

NCT02091648
View directory record Official record
Conditions
Asthma
Interventions
I Can Cope Intervention, Standard Education Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 14 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 4, 2026, 10:33 PM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

NCT01953120
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Belatacept
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 4, 2026, 10:33 PM EDT
Active, not recruiting Not applicable Interventional

Stress and Blood Pressure Management for Caregivers

NCT05734638
View directory record Official record
Conditions
Hypertension, Stress, Psychological
Interventions
MIM-DASH, MIM Only, DASH Only
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
40 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 4, 2026, 10:33 PM EDT
Recruiting Not applicable Interventional

WEAVE NM: Heart Health and Nutrition for Life

NCT07074145
View directory record Official record
Conditions
Hypertension
Interventions
Heart Health and Nutrition for Life (HHNL), Self-Measured Blood Pressure
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 84 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 4, 2026, 10:33 PM EDT